The Impact of R&D Cooperations and Mergers in Pharmaceuticals on Research Activities and Drugs Offered on the Market
The Impact of R&D Cooperations and Mergers in Pharmaceuticals on Research Activities and Drugs Offered on the Market
复制标题
DOI：
10.1002/soej.12221
复制
发表时间：
2017-07
期刊：
影响因子：
--
通讯作者：
Tannista Banerjee;R. Siebert
中科院分区：
文献类型：
--
作者：
Tannista Banerjee;R. Siebert
在过去10年中，制药行业经历了前所未有的价格急剧上涨，这通常归因于药物开发成本的增加。为了应对飞速增长的开发成本，公司开始进行研发合作。我们研究了研发合作对企业研究活动和市场上提供的药物的影响。利用一个综合数据集，我们发现在药物开发过程的早期阶段形成的研发合作增加了研发项目的数量和市场上提供的药物数量。大型企业在技术和产品市场上形成的后期研发合作增加了企业的研究活动，但减少了在产品市场上推出的药物数量。研究结果表明，在研究后期进行合作的大公司会重新优化其研发管道，并消除类似的研究项目。
In the last 10 years, the pharmaceutical industry has experienced steep, unprecedented price increases which are frequently attributed to increasing drug development costs. To cope with rocketing development costs, companies engage in Research and Development (R&D) cooperations. We study the impact of R&D cooperations on firms' research activities and drugs offered on the market. Using a comprehensive dataset, we find that R&D cooperations formed at the early stage of the drug development process increase the number of R&D projects and the number of drugs offered on the market. Late stage R&D cooperations, formed among larger firms in technology and product markets, increase firms' research activities, but reduce the number of drugs launched on the product market. Results suggest that large firms cooperating in the late research stage re-optimize their R&D pipelines and eliminate similarly aligned research projects.